Zacks Research Issues Optimistic Outlook for NTLA Earnings

Key Points

• Zacks Research has improved its earnings per share (EPS) forecast for Intellia Therapeutics, now expecting a loss of ($1.16) for Q3 2025, up from a prior estimate of ($1.19).
• The company reported EPS of ($0.99) for the last quarter, surpassing analyst expectations by $0.04, with a notable revenue increase of 104.3% year-over-year.
• Multiple analysts have recently adjusted their price targets for Intellia Therapeutics, with most rating the stock as a Buy, indicating a consensus average price target of $29.05.

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Analysts at Zacks Research raised their Q3 2025 EPS estimates for Intellia Therapeutics in a note issued to investors on Monday, September 8th. Zacks Research analyst Team now anticipates that the company will post earnings of ($1.16) per share for the quarter, up from their previous estimate of ($1.19). The consensus estimate for Intellia Therapeutics' current full-year earnings is ($5.07) per share. Zacks Research also issued estimates for Intellia Therapeutics' Q4 2025 earnings at ($1.25) EPS, FY2025 earnings at ($4.50) EPS, Q1 2026 earnings at ($1.19) EPS, Q2 2026 earnings at ($1.21) EPS, Q3 2026 earnings at ($1.07) EPS, Q4 2026 earnings at ($1.12) EPS, FY2026 earnings at ($4.59) EPS, Q1 2027 earnings at ($0.89) EPS, Q2 2027 earnings at ($1.04) EPS and FY2027 earnings at ($4.21) EPS.

NTLA has been the subject of several other reports. HC Wainwright lowered their price objective on shares of Intellia Therapeutics from $30.00 to $25.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Canaccord Genuity Group decreased their target price on shares of Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating for the company in a research report on Tuesday, June 3rd. Wells Fargo & Company restated an "overweight" rating and set a $45.00 target price (down from $50.00) on shares of Intellia Therapeutics in a research report on Friday, August 8th. Wall Street Zen upgraded shares of Intellia Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, September 6th. Finally, Wedbush restated a "neutral" rating and set a $7.00 target price on shares of Intellia Therapeutics in a research report on Monday, June 16th. Eleven investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $27.11.

Intellia Therapeutics Trading Up 2.2%

Shares of NASDAQ:NTLA traded up $0.25 on Wednesday, hitting $11.67. 2,116,342 shares of the company were exchanged, compared to its average volume of 4,090,562. Intellia Therapeutics has a 1-year low of $5.90 and a 1-year high of $23.76. The stock's 50 day moving average price is $11.62 and its 200 day moving average price is $9.60. The firm has a market capitalization of $1.25 billion, a P/E ratio of -2.48 and a beta of 2.28.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.99) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.04. Intellia Therapeutics had a negative net margin of 908.48% and a negative return on equity of 57.48%. The business had revenue of $14.25 million during the quarter, compared to the consensus estimate of $12.26 million. During the same period in the previous year, the firm posted ($1.52) earnings per share. The business's revenue for the quarter was up 104.3% compared to the same quarter last year.

Hedge Funds Weigh In On Intellia Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new position in Intellia Therapeutics in the 4th quarter valued at about $25,000. Headlands Technologies LLC acquired a new position in Intellia Therapeutics in the 2nd quarter valued at about $26,000. Whipplewood Advisors LLC boosted its holdings in Intellia Therapeutics by 114,900.0% in the 2nd quarter. Whipplewood Advisors LLC now owns 3,450 shares of the company's stock valued at $32,000 after purchasing an additional 3,447 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in Intellia Therapeutics by 56.4% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company's stock valued at $33,000 after purchasing an additional 1,655 shares during the last quarter. Finally, Harbour Investments Inc. lifted its holdings in shares of Intellia Therapeutics by 76.7% in the 1st quarter. Harbour Investments Inc. now owns 5,214 shares of the company's stock worth $37,000 after acquiring an additional 2,264 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Intellia Therapeutics news, EVP Edward J. Dulac III sold 7,462 shares of the business's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $14.02, for a total value of $104,617.24. Following the transaction, the executive vice president directly owned 106,062 shares in the company, valued at $1,486,989.24. The trade was a 6.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director William J. Chase bought 100,000 shares of the firm's stock in a transaction on Wednesday, August 20th. The stock was purchased at an average price of $10.03 per share, for a total transaction of $1,003,000.00. Following the completion of the acquisition, the director directly owned 134,693 shares in the company, valued at $1,350,970.79. The trade was a 288.24% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 12,534 shares of company stock valued at $153,837. 3.10% of the stock is owned by corporate insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.